Dynavax Technologies Corporation (DVAX)

Last Price: 4.17 (2020-10-21)

Company Description

Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $35.22M
Net Income (Most Recent Fiscal Year) $-152.60M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 13.43
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 6.74
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -386.93%
Net Margin (Trailing 12 Months) -386.93%
Return on Equity (Trailing 12 Months) -372.34%
Return on Assets (Trailing 12 Months) -37.46%
Current Ratio (Most Recent Fiscal Quarter) 4.99
Quick Ratio (Most Recent Fiscal Quarter) 3.97
Debt to Common Equity (Most Recent Fiscal Quarter) 3.08
Inventory Turnover (Trailing 12 Months) 0.21
Book Value per Share (Most Recent Fiscal Quarter) $0.10
Earnings per Share (Most Recent Fiscal Quarter) $-0.27
Earnings per Share (Most Recent Fiscal Year) $-1.87
Diluted Earnings per Share (Trailing 12 Months) $-1.71
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 109.51M
Free Float 94.91M
Market Capitalization $466.52M
Average Volume (Last 20 Days) 2.75M
Beta (Past 60 Months) 1.03
Percentage Held By Insiders (Latest Annual Proxy Report) 13.33%
Percentage Held By Institutions (Latest 13F Reports) 73.68%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%